- Poster presentation
- Open Access
In vivo mri of the left coronary artery branching patterns in mice and the myocardial area-at-risk during coronary ligation: towards improved understanding of an important model
© Dai et al; licensee BioMed Central Ltd. 2010
- Published: 21 January 2010
- Anterior Wall
- Left Coronary Artery
- Short Axis Slice
- Gadolinium Chelate
- Coronary Ligation
Ligation of the left coronary artery (LCA) is frequently used to study ischemia in mice. However, the branching pattern of the LCA in mice and the impact of this has not been characterized. MRI of LCA branching patterns was thus performed in mice in vivo and correlated with fluorescence reflectance imaging (FRI) of the percent myocardial area at risk (AAR) during coronary ligation.
MRI was performed on a 9.4 T horizontal bore small animal scanner. A 1500 mT/m gradient insert (Resonance Research Inc) was used to minimize the TE without sacrificing spatial resolution. FLASH cines were acquired in the plane of the lateral wall of the left ventricle with the following parameters: FOV 25 mm, slice 1 mm, MTX 256 × 256 (in-plane resolution 97 um), flip angle 60°, TE 1 ms, 16 frames per RR interval, Nex 8. Images were acquired in 6 mice after injection of an albumin-bound gadolinium chelate and in 5 without the contrast agent. The percent AAR was calculated in 10 mice in 1) The surgeon's view looking down onto the anterior wall of the whole heart and 2) in 1 mm thick short axis slices.
In most mice numerous branches arise from the LCA in the anterolateral wall and course towards the posterolateral apex. The extent of ischemia in the anterior wall is quite consistent. However, due to the branching pattern of the LCA, minor differences in the placement of the ligation can result in either extensive or virtually no ischemia in the lateral and posterolateral walls. Intra-operative inspection by the surgeon of blanching in the anterior wall thus usually overestimates the global extent of ischemia (Fig 1F).
This article is published under license to BioMed Central Ltd.